Fennec Pharmaceuticals Inc — Balance Sheet (NASDAQ:FENC) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Total assets 31.42 M22.41 M26.94 M26.86 M44.95 M Total liabilities 2.35 M6.64 M29.51 M38.49 M50.82 M Total equity 29.07 M15.77 M2.57 M11.62 M5.87 M Total liabilities & shareholders' equities 31.42 M22.41 M26.94 M26.86 M44.95 M Total debt ————— Net debt —————

News

Certara, Inc. (CERT) Q4 Earnings Lag Estimates

Apellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue Estimates

Fennec Pharmaceuticals: A Compelling Single-Asset Growth Story For 2026 (NASDAQ:FENC)

City of Hope to study PEDMARK for hearing protection in testicular cancer

Pedmark livre une étude au Japon - Moins de perte auditive, même puissance dans la lutte contre le cancer | Benzinga France

Fennec’s pediatric hearing protection drug shows positive results in Japan

Pedmark Delivers In Japan Study — Less Hearing Loss, Same Cancer-Fighting Power - Fennec Pharmaceuticals (NASDAQ:FENC)

Fennec Pharmaceuticals repays all outstanding convertible notes

Fennec Pharmaceuticals raises $5 million in non-brokered offering

Fennec Pharmaceuticals raises $40.25 million through public offering

Fennec Pharmaceuticals plans $5 million share offering to existing investors

Fennec Pharmaceuticals prices $35 million public offering